OBI Pharma Inc (台灣浩鼎) shares plunged yesterday after a story by the Chinese-language Next Magazine rekindled controversies about the biotechnology firm’s clinical trial setbacks and insider trading.
The stock fell 4.34 percent to NT$397 on the Taipei Exchange, reaching its lowest closing price since May.
The report suggested that progress on OBI-822 — the company’s breast cancer drug — had fallen short of expectations.
The report said that in anticipation of unfavorable results from the clinical trial, OBI had consulted five experts from Taiwan’s medical sector during a meeting on Aug. 28 last year, and decided to wrap up the study and “unblind” the study data ahead of schedule.
The company also changed the metrics for data interpretation from central reading to local reading so that the drug might appear to be more effective, the report said.
In February, the company released OBI-822’s clinical trial results and said that the outcome showed “no statistical significance.”
Since then, the company’s share price has swung wildly, with authorities looking into allegations of market manipulation and other contraventions.
Vice President Chen Chien-jen (陳建仁), who holds a doctorate in human genetics and was one of the five people the company consulted, was questioned by investigators as a witness in May.
Investigators have decrypted tens of thousands of e-mails between former Academia Sinica president Wong Chi-huey (翁啟惠), who had collaborated in the development of OBI-822, and OBI Pharma chairman Michael Chang (張念慈), the report said.
The e-mails showed that Wong held and traded OBI Pharma shares and had on numerous occasions sought research funds and cash to purchase company shares from Chang, the report said.
The report suggests that Wong contradicted his claims that he was not financially involved with OBI Pharma.
Chen’s office said he was called in as a witness to answer questions related to a case against Chang’s alleged violation of the Securities and Exchange Act (證券交易法), and that the report’s claims about the meeting with OBI Pharma were false.
OBI Pharma said that Chang had donated US$300,000 for a Scripps Research Institute laboratory, where Wong is a professor of chemistry specializing in glycoscience, and that the transfer of funds had nothing to do with the personal relationship between Wong and Chang.
It added that the five experts it consulted are not financially involved with the company.
The company said it is not uncommon for a drug developer to change clinical data methodologies, as seen in many precedents in Taiwan and in the US.
The company’s chief medical officer Nathan Chen (陳純誠), who had overseen the clinical trials, resigned on Aug. 11.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
FUTURE PLANS: Although the electric vehicle market is getting more competitive, Hon Hai would stick to its goal of seizing a 5 percent share globally, Young Liu said Hon Hai Precision Industry Co (鴻海精密), a major iPhone assembler and supplier of artificial intelligence (AI) servers powered by Nvidia Corp’s chips, yesterday said it has introduced a rotating chief executive structure as part of the company’s efforts to cultivate future leaders and to enhance corporate governance. The 50-year-old contract electronics maker reported sizable revenue of NT$6.16 trillion (US$189.67 billion) last year. Hon Hai, also known as Foxconn Technology Group (富士康科技集團), has been under the control of one man almost since its inception. A rotating CEO system is a rarity among Taiwanese businesses. Hon Hai has given leaders of the company’s six